Form 4: Recursion Pharmaceuticals Director Insider Transaction

Director Christopher Gibson executed a conversion and sale of Class A Common Stock pursuant to a Rule 10b5-1 trading plan.

Summary

• Director Christopher Gibson converted 60,000 shares of Class B Common Stock into Class A Common Stock.
• Following the conversion, 40,000 shares of Class A Common Stock were sold at a price of $3.37 per share.
• An additional 20,000 shares were disposed of via a gift transaction.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by an insider.

Positives

• Transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a systematic approach to liquidity rather than reactive selling.

Negatives

• The director reduced his direct beneficial ownership of Class A Common Stock from 966,556 to 906,556 shares.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives and directors in the biotechnology sector to manage personal liquidity and tax obligations without signaling negative sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with standard corporate governance practices for publicly traded biotech firms.
• The volume of shares sold represents a small fraction of the director's total beneficial ownership.

Related Party Transactions

• The reporting person maintains beneficial ownership through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed under a pre-planned 10b5-1 arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Biotech, Director Transaction